About this document
HIMS: FDA Review on Tirzepatide Impact by tsfnexusstudio is a document available to read on EtoBox.
Truist Securities reports that the FDA is reviewing its decision regarding the shortage of Tirzepatide, allowing compounding pharmacies to continue producing it, which is favorable for Hims & Hers Health, Inc. (HIMS). Despite maintaining a
- Author
- tsfnexusstudio
- Language
- EN